A new class of weight-loss drugs is changing the food industry, but not in the way many expected at first. They could present ...

In Quebec, anti-obesity medications are on the list of exclusions of the Régie de l’assurance maladie du Québec (RAMQ). Quebec is the only Canadian province that does not evaluate obesity medications ...

Semaglutide outperformed 7 diabetes medications in reducing risk of Alzheimer's disease, according to a study of over 1 ...

GLP-1 drugs like Wegovy (NVO) might help with weight loss, but they aren’t leading to lower health care costs yet, according ...

A new study shows otherwise healthy adults who take broad-spectrum antibiotics to treat community-acquired pneumonia are more likely to suffer adverse drug events. Also in the news: evolution of covid ...

Semaglutide medications — such as Ozempic, the popular diabetes medication — have been linked to a reduced risk of Alzheimer’s disease for certain groups, a new study finds.

Sanofi and CD&R entered into exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella.

Wegovy and similar weight-loss medications are becoming widely prescribed for teenagers with obesity, but little is known ...

The U.K. government issued a new warning aimed at the misuse of GLP-1 therapies by those who don’t qualify for the meds but are instead using them for quick-fix weight loss.

As the demand for weight loss injectables soars, so too does the market for off-brand alternatives, some of which may not be ...

The Dow, S&P 500, and Nasdaq were mixed Friday as the stock market digested the latest earnings and economic data.

The UK’s AstraZeneca, which is working on an oral GLP-1, also views the drugs as part of a combination strategy. In other ...